# US 2008/0287675 A1 · Cascade system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287675 A1
- Document ID: US20080287675A1
- Status: Published application
- Kind: A1
- Application number: 12/120,868
- Filed: 2008-05-15
- Published: 2008-11-20
- Earliest claimed: 2007-05-18
- Assignees: Abbott Laboratories
- Inventors: Yao-En Li
- Web page: https://patentgrep.com/patent/US20080287675A1

## CPC

- C07D 498/18: Bridged systems
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of purifying an active pharmaceutical ingredient sufficient for administration into a human subject can include: obtaining a reaction product composition having the active pharmaceutical ingredient and impurities, wherein said active pharmaceutical ingredient is rapamycin or a rapamycin analog; introducing the reaction product composition into a first column of a chromatography system; directing a first portion of a first elutant from the first column to waste, said first portion having more impurity than active pharmaceutical ingredient; directing a second portion of the first elutant from the first column into a second column, said second portion having more active pharmaceutical ingredient than impurity; collecting factions of a second elutant from the second column that include the active pharmaceutical ingredient; and concentrating the said collected fractions to obtain a purity of the active pharmaceutical ingredient greater than 98% and with less than or about 0.95% being first and second major impurities.

## Claims

### Claim 1

A method of purifying an active pharmaceutical ingredient sufficient for administration into a human subject, the method comprising:
obtaining a reaction product composition having the active pharmaceutical ingredient and impurities, wherein said active pharmaceutical ingredient is rapamycin or a rapamycin analog;
introducing the reaction product composition into a first column of a chromatography system;
directing a first portion of a first elutant from the first column to waste;
directing a second portion of the first elutant from the first column into a second column without processing the second portion of the first elutant before entering the second column;
collecting factions of a second elutant from the second column that include the active pharmaceutical ingredient; and
concentrating said collected fractions to obtain a purity of the active pharmaceutical ingredient greater than 98% and with less than or about 0.95% being first and second major impurities.

### Claim 2 (depends on 1)

A method as in claim 1, wherein the active pharmaceutical ingredient is a rapamycin analog.

### Claim 3 (depends on 2)

A method as in claim 2, wherein the active pharmaceutical ingredient has a chemical structure of Formula 1 or derivative thereof:

### Claim 4 (depends on 3)

A method as in claim 3, wherein the active pharmaceutical ingredient has a chemical structure of Formula 2 or derivative thereof:

### Claim 5 (depends on 3)

A method as in claim 3, wherein the first major impurity is a retro-aldol, and the second major impurity is a N1-lutidine tetrazole adduct.

### Claim 6 (depends on 5)

A method as in claim 5, wherein the chromatography system is a cascade system with an isocratic solvent system.

### Claim 7 (depends on 6)

A method as in claim 6, wherein the isocratic solvent system is THF and heptane.

### Claim 8 (depends on 6)

A method as in claim 6, wherein the concentrated active pharmaceutical ingredient has a purity of greater than or about 98.5% and the first major impurity is less than or about 0.85% and the second major impurity is less than or about 0.1%.

### Claim 9 (depends on 5)

A method as in claim 5, wherein the chromatography system is a cascade system with a step gradient solvent system.

### Claim 10 (depends on 9)

A method as in claim 9, wherein the step gradient solvent system includes the following:
a first solvent introduced into the first column during a first time period between the introduction of the reaction product composition into a first column and the directing of the second portion of the first elutant from the first column into the second column; and
a second solvent introduced into the first column during a second time period after directing the second portion of the first elutant from the first column into the second column.

### Claim 11 (depends on 10)

A method as in claim 10, wherein the first solvent includes a first ratio of THF/heptate and the second solvent includes a second ratio of THF/heptane, and wherein the first ratio is less than the second ratio.

### Claim 12 (depends on 10)

A method as in claim 10, wherein the concentrated active pharmaceutical ingredient has a purity of greater than or about 99% and the first major impurity is less than or about 0.40% and the second major impurity is less than or about 0.1%.

### Claim 13

A method of purifying a rapamycin analog sufficient for administration into a human subject, the method comprising:
obtaining a reaction product composition having the rapamycin analog and impurities;
introducing the reaction product composition into a first column of a cascade system with an isocratic solvent system;
directing a first portion of a first elutant from the first column to waste;
directing a second portion of the first elutant from the first column into a second column without processing the second portion of the first elutant before entering the second column;
collecting factions of a second elutant from the second column that include the active pharmaceutical ingredient; and
concentrating said collected fractions to obtain a purity of the active pharmaceutical ingredient greater than 98% and with less than or about 0.95% being first and second major impurities;
wherein said rapamycin analog has a chemical structure of Formula 1 or derivative thereof:

### Claim 14 (depends on 13)

A method as in claim 13, wherein the active pharmaceutical ingredient has a chemical structure of Formula 2 or derivative thereof:

### Claim 15 (depends on 13)

A method as in claim 13, wherein the first major impurity is a retro-aldol, and the second major impurity is a N1-lutidine tetrazole adduct.

### Claim 16 (depends on 5)

A method as in claim 5, wherein the isocratic solvent system is THF and heptane.

### Claim 17 (depends on 15)

A method as in claim 15, wherein the concentrated active pharmaceutical ingredient has a purity of greater than or about 98.5% and the first major impurity is less than or about 0.85% and the second major impurity is less than or about 0.1%.

### Claim 18

A method of purifying a rapamycin analog sufficient for administration into a human subject, the method comprising:
obtaining a reaction product composition having the rapamycin analog and impurities;
introducing the reaction product composition into a first column of a cascade system with a step gradient solvent system;
directing a first portion of a first elutant from the first column to waste;
directing a second portion of the first elutant from the first column into a second column without processing the second portion of the first elutant before entering the second column;
collecting factions of a second elutant from the second column that include the active pharmaceutical ingredient; and
concentrating said collected fractions to obtain a purity of the active pharmaceutical ingredient greater than 98% and with less than or about 0.95% being first and second major impurities;
wherein said rapamycin analog has a chemical structure of Formula I or derivative thereof:

### Claim 19 (depends on 18)

A method as in claim 18, wherein the active pharmaceutical ingredient has a chemical structure of Formula 2 or derivative thereof:

### Claim 20 (depends on 18)

A method as in claim 18, wherein the first major impurity is a retro-aldol, and the second major impurity is a N1-lutidine tetrazole adduct.

### Claim 21 (depends on 19)

A method as in claim 19, wherein the step gradient solvent system includes the following:
a first solvent introduced into the first column during a first time period between the introduction of the reaction product composition into a first column and the directing of the second portion of the first elutant from the first column into the second column; and
a second solvent introduced into the first column during a second time period after directing the second portion of the first elutant from the first column into the second column.

### Claim 22 (depends on 21)

A method as in claim 21, wherein the first solvent includes a first ratio of THF/heptate and the second solvent includes a second ratio of THF/heptane, and wherein the first ratio is less than the second ratio.

### Claim 23 (depends on 22)

A method as in claim 22, wherein the concentrated active pharmaceutical ingredient has a purity of greater than or about 99% and the first major impurity is less than or about 0.40% and the second major impurity is less than or about 0.11%.
